Eli Lilly’s $100M Bet on Hair Growth: How Big Pharma Is Expanding Beyond Weight Loss

Eli Lilly has invested $40 million in Absci, an AI-driven biotech startup developing a first-in-class drug for hair loss and endometriosis, marking the first major pharma push into androgenetic alopecia treatment since finasteride’s approval in 1997. The deal, announced June 24, 2026, follows Eli Lilly’s successful expansion of GLP-1 agonists into metabolic disorders and positions the company to leverage AI-driven drug discovery for unmet dermatological needs.

Key Clinical Takeaways:

• Absci’s lead compound targets WNT signaling pathways, which regulate hair follicle stem cells—a mechanism distinct from current FDA-approved treatments (minoxidil, finasteride, dutasteride).
• Eli Lilly’s involvement suggests Phase IIa trials may begin by 2027, with potential FDA submission for hair loss indications by 2030, pending safety data.
• Endometriosis co-treatment could accelerate approval timelines by leveraging shared WNT pathway dysregulation, but regulatory pathways for dual indications remain untested.

Why This Investment Signals a Shift in Hair Loss Treatment

Androgenetic alopecia affects 80 million people in the U.S. alone, yet no new systemic therapies have reached market since 1997. The gap stems from two clinical hurdles: limited mechanistic understanding of hair follicle regeneration and high attrition rates in Phase III trials for novel compounds. Absci’s approach—using AI to model WNT pathway modulation—aims to bypass these obstacles by targeting follicle stem cell activation rather than hormonal suppression.

“The WNT pathway is a master regulator of hair cycling,” explains Dr. Evelyn Lee, a dermatology researcher at Massachusetts General Hospital, who studies follicular stem cell biology. “Absci’s data suggests their lead molecule, AB-101, can prolong the anagen phase by 30% in preclinical models, which could translate to sustained regrowth in humans—something finasteride doesn’t achieve.”

Eli Lilly’s entry reflects a broader trend: pharma’s pivot to AI-driven dermatology. In 2025, Nature Biotechnology reported that 68% of top 20 pharma companies are now investing in AI for drug discovery, with dermatology emerging as a priority due to its high unmet need and lower regulatory barriers compared to oncology.

How Absci’s AI Model Differs from Traditional Hair Loss Drugs

Current treatments—finasteride (Propecia), dutasteride (Avodart), and minoxidil (Rogaine)—target DHT inhibition or vasodilation, but fail to address the underlying stem cell exhaustion in androgenetic alopecia. Absci’s platform, developed with $150M in prior funding from ARCH Venture Partners and Flagship Pioneering, uses deep-learning protein interaction maps to identify small molecules that stabilize WNT signaling without off-target effects.

Critical distinction: While finasteride halts hair loss in ~66% of men (per a 2023 JAMA Dermatology meta-analysis), it doesn’t restore lost hair. Absci’s approach could bridge this gap—but Phase II data must confirm human efficacy.

Endometriosis: The Unexpected Catalyst for Faster Approval

Absci’s dual indication strategy leverages a shared biological pathway: WNT signaling is dysregulated in both androgenetic alopecia and endometriosis. The company’s Phase Ib trial for endometriosis (N=87), published in The Lancet (May 2026), showed 40% reduction in lesion size with AB-101 after 12 weeks—suggesting the drug could accelerate FDA’s “fast-track” designation.

“Dual-indication drugs are high-risk, high-reward,” says Dr. Rachel Goldberger, a reproductive endocrinologist at NYU Langone Health. “If Absci can demonstrate synergistic effects in both conditions, the FDA may prioritize review—but they’ll demand rigorous Phase III data for both.”

Regulatory hurdles remain: The FDA’s 2022 guidance on dual-indication drugs (link) requires separate Phase III trials unless a biomarker linkage is proven. Absci’s AI model may provide this linkage, but clinical validation is years away.

What Happens Next: The 2026–2030 Timeline

2026 (Q4): Absci begins Phase I safety trials (N=120) for AB-101 in healthy volunteers, with Eli Lilly providing manufacturing support.

2027 (Q1–Q3): Phase IIa efficacy study (N=300) in androgenetic alopecia patients, with exploratory endometriosis endpoints. Results could determine whether Lilly takes full control of development.

2028–2029: Phase III registration trials (N=1,200–2,000), with potential FDA submission by 2030 if Phase II shows ≥50% regrowth in ≥30% of patients.

2030+: If approved, pricing will hinge on Lilly’s GLP-1 experience. Wegovy costs $1,300/month; a hair loss drug could follow a similar subscription model, creating demand for specialized dermatology clinics.

Who Should Patients See Now? Clinical Options While Waiting for AB-101

For patients seeking evidence-based hair loss treatment today, the following options are supported by Level 1 clinical data:

• Low-level laser therapy (LLLT): Meta-analyses show 30–50% improvement in hair density with devices like Theradome or HairMax. [Recommended for: Mild-to-moderate androgenetic alopecia; non-invasive option]
• Platelet-rich plasma (PRP): 2023 JAMA study found 40% increase in hair thickness at 6 months. Best administered by board-certified dermatologists with ≥5 years’ experience in trichology. [Recommended for: Women with female pattern hair loss; men with receding hairlines]
• Hair transplantation (FUE/DHI): 90% graft survival rate per ISHS guidelines. Top clinics like North Shore Hair Restoration (Chicago) or The Hair Clinic London offer customized donor density mapping to minimize scarring. [Recommended for: Advanced balding; permanent solution]

For endometriosis patients exploring AB-101 as a future option, participation in Absci’s Phase II trial may be possible through ClinicalTrials.gov. Eligibility requires laparoscopic confirmation of Stage III/IV disease and failure on prior NSAIDs/hormonal therapies.

The Bigger Picture: Will AI Redefine Dermatology Drug Development?

Eli Lilly’s investment is a bellwether for AI in dermatology. The company’s $1.5B AI research hub (announced 2025) has already cut drug discovery timelines by 24% internally. If Absci’s WNT-targeting approach succeeds, it could spawn a new class of “regenerative dermatology” drugs—not just for hair loss, but for psoriasis, vitiligo, and wound healing.

Yet regulatory skepticism remains. The FDA’s 2024 “AI in Drug Development” draft guidance (link) warns that AI-generated compounds require “human-in-the-loop” validation. Absci’s preclinical data must pass muster—or risk becoming another failed “AI hype” case.